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doi:10.1016/j.jtcvs.2004.02.020THeart failure has reached epidemic proportions over the last severalyears. It may be no small coincidence that the incidence of obesityis also on the rise. Women tend to have a higher prevalence ofheart failure over age 75. This may contribute to their relativeunderrepresentation as heart transplant and ventricular assist de-vice (VAD) recipients. Total body surface area is also an issue
with respect to certain VADs.
The most recent registry report of the International Society for Heart and Lung
Transplantation (ISHLT) revealed that only 34.1% of donors were female.1 The
female heart donor in a female heart recipient may be responsible for an increased
risk of interstitial myocardial fibrosis. As heart transplant recipients, women need a
donor within 30% of their weight. A larger donor is indicated for the recipient with
high pulmonary vascular resistance. Female recipients of cardiac transplantation
have been reported to have an increased mortality when compared with male
recipients.2 Various immunologically related conditions, such as systemic lupus
erythematosus and rheumatoid arthritis, are found in increased prevalence among
women. Further, there is experimental evidence to suggest that fundamental immune
responses, such as antibody production and rejection of allogeneic grafts, are
potentiated in females. Thus, it is not surprising that studies have shown that female
cardiac allograft recipients have a higher risk of cardiac rejection and the subsequent
need for increased immunosuppression.3 How this affects survival in female patients
remains to be seen. However, it certainly suggests that an earlier diagnosis and
management of alloreactivity in female recipients before the development of acute
rejection and the use of more focused and less global immunosuppressive therapy
may significantly affect the outcome of female cardiac allograft recipients. Also, an
increased risk of sensitization may be seen in multiparous females, especially when
associated with placement of a left ventricular assist device (LVAD). Patients who
are highly sensitized can be pretreated with intravenous immunoglobulin (IVIg) in
preparation for heart transplantation.4 Cyclophosphamide is also given in addition to
IVIg as part of the desensitization regimen.
As a woman progresses through life from neonate to elderly, certain interven-
tional options for the treatment of heart failure are available. As a neonate, bridging
to transplantation is done with extracorporeal membrane oxygenation (ECMO). The
most common age for pediatric heart transplantation is now between 1 day and 1
year.5 With ECMO, there are no gender issues. Female subjects are well represented
in a large review from the Deutsches Herzzentrum Berlin.6 They examined 95
children who underwent elective heart transplantation, emergency heart transplan-
tation, and bridging to heart transplantation with a pulsatile pneumatic assist device.
The group was 55 boys and 40 girls. Eighteen received a VAD and 8 of these were
female. Gender did not affect survival, but a preoperative diagnosis of congenital
heart disease did.
At the adolescent level, girls tend to react better to a heart transplant from an
academic and social vantage point. Boys, however, do better physically. The
adolescent who has viral myocarditis often undergoes implantation of an LVAD.
The dramatic hemodynamic and physiologic improvement seen in this subgroup of
patients makes them better candidates for a bridge to recovery and explant of the
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for postpartum cardiomyopathy, myocarditis, or dilated car-
diomyopathy. Postpartum cardiomyopathy may respond to
unloading of the heart with a device and eventual device
removal. As they leave childbearing years behind, more
women have ischemic cardiomyopathy like their male coun-
terparts, although at a somewhat older age. Women com-
prise only 22.4% of heart transplant recipients. Women
have had children after heart transplantation. The increased
plasma volume of pregnancy does stress a transplanted
heart. Postmenopausal heart transplant recipients are at in-
creased risk for osteoporosis. Weaning from steroids is
helpful when appropriate.
Technically, heart transplantation in women is no differ-
ent from that in men. If a complex reconstruction has been
performed for congenital heart disease, transesophageal
echocardiogram is a useful adjunct. The left atrial anasto-
mosis is performed first, then the inferior vena caval anas-
tomosis, the superior vena caval anastomosis, followed by
the pulmonary arterial and aortic anastomoses. Care is taken
to avoid narrowing either caval anastomosis or kinking of
the pulmonary arterial anastomosis. Women tend to require
transfusion more frequently than men after conventional
heart surgery.7 This is probably also true after heart trans-
plantation. Women with osteoporosis undergo sternal clo-
sure using figure-of-8 wire closure to reduce the incidence
of sternal wound-related problems.
The results of the REMATCH trial (Randomized Eval-
uation of Mechanical Assistance for the Treatment of Con-
gestive Heart Failure) showed that in a randomized group of
patients with class IV heart failure, those who received an
LVAD had a 48% reduction in risk of death compared with
the group receiving medical management.8 The type of
VAD a woman receives is based on (1) size of patient, (2)
degree of heart failure, and (3) whether or not she is a
transplant candidate. The Novacor LVAD (Baxter Health-
care Corp, Novacor Div, Oakland, Calif) and Thoratec VE
HeartMate LVAD (Thermo Cardiosystems, Inc, Woburn,
Mass) require a body surface area of greater than 1.5 m2.
The Berlin Heart (Berlin Heart AG, Berlin, Germany) is
extracorporeal and allows a lower body surface area. This is
why it was used in children; however, it is not approved by
the Food and Drug Administration. For patients with severe
cardiogenic shock, an Abiomed (Abiomed, Inc, Danvers,
Mass), Thoratec, or total artificial heart is used.9 These
patients usually have right and left heart failure and some
element of end organ failure. Patients with early decompen-
sation of chronic congestive heart failure who are heart
transplant recipients undergo placement of a HeartMate or
Novacor VAD. Patients who are not transplant candidates,
or who may recover heart function, receive an Abiomed,
Thoratec, or centrifugal pump and are weaned within 1
week. Abiomed and centrifugal pumps can be a bridge to
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Mate, or Novacor devices. In a very recent article, a 15-year
experience is reported using the CardioWest total artificial
heart (CardioWest Technologies, Inc, Tucson, Ariz) as a
bridge to transplantation.10 Of the 127 patients, only 19
were women. Small body size was associated with increased
operative mortality. Only 4 of 9 with a body surface area of
less than 1.6 m2 survived to transplantation. These smaller
patients are better served with a biventricular pneumatic
device (Thoratec).
Technically, women who are short, with not much length
to their aortas, can be challenging recipients of a HeartMate
or Novacor VAD. Circulatory arrest has even been used to
deal with a lack of aorta when removing the VAD and
performing the heart transplant. Smaller women have had
difficulty with the abdominal placement of the pump. Pre-
vious left upper quadrant surgery or a long narrow rib cage
can also contribute to difficulties intraoperatively, as well as
to postoperative pain. Right ventricular dysfunction after
LVAD insertion does not appear to be related to gender.11
Quality of life issues are being evaluated after heart
transplantation and/or VAD insertion in women. Fifty
women who were status-post heart transplantation filled out
a Herth Hope Index, Multiple Affect Adjective Checklist,
and SF-12.12 This study revealed that they had moderately
low hope and relatively high anxiety, depression, and hos-
tility. Hope was found to be an independent predictor of
mood and quality of life. A certain patient of mine, who had
had redo sternotomy and heart transplantation a few years
earlier, would say, “I’m in pretty good shape for the shape
I’m in.” A positive attitude works, but providing false hope
is not a kindness to the patient or her family.
Interestingly, in a study on the change in the quality of
life after LVAD implementation to after heart transplanta-
tion, only 1 patient was a woman (out of 40).13 Another
review of lifestyle and quality of life in long-term survivors
of cardiac transplant included only 8 women among 93
patients. The investigators did realize that their study find-
ings could not be applied to women because of their under-
representation.14
As health care providers, we ask a lot of our patients,
regardless of gender. We ask them to take any number of
medications; learn how to take care of a mechanical assist
device; go through one, two, or several operations; and then
take more medications. As we gain in experience with
respect to heart transplantation and devices, questions re-
garding quality of life must be asked. Answers for women
will lag behind until their representation is increased and the
clinical database reflects their participation. In the future,
women may receive more devices as destination therapy is
more frequently applied in older patients and as devices are
designed for use in smaller patients.
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